Development of imaging methods that contribute to the elucidation of the pathological mechanism of amyloid-related imaging abnormalities and the safety monitoring

Development of imaging methods that contribute to the elucidation of the pathological mechanism of amyloid-related imaging abnormalities and the safety monitoring - Development of imaging methods that contribute to the elucidation of the pathological mechanism of amyloid-related imaging abnormalities and the safety monitoring

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055333

Enrollment

100

Registered

2024-08-26

Start date

2024-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The study participants comprised consecutive patients to whom anti-Abeta monoclonal antibodies were administered between May 2024 and October 2024. The diagnosis and clinical staging for individuals on the Alzheimer disease continuum were made based on the Alzheimer Association Workgroup. The patients who agreed to participate in this study were scanned with DP-pCASL and multiple spoiled gradient echo sequences for the evaluation of ARIA pathomechanisms in addition to conventional MRI sequences, including T2-weighted image and FLAIR, for the ARIA diagnosis.

Exclusion criteria

Exclusion criteria: Patients who cannot be administered Abeta monoclonal antibodies or who did not consent to testing.

Design outcomes

Primary

Measure	Time frame
Associations between cognitive function tests and imaging biomarkers (BBB water exchange rate as kw index, paramagnetism, diamagnetism)	—

Countries

Japan,North America

Contacts

Public ContactYuto Uchida

Nagoya City University Neurology

uchidayuto0720@yahoo.co.jp052-853-8094

Outcome results